<html>

<head>
    <link href="./static/vendor/bootstrap/css/bootstrap.css" rel="stylesheet">
    <link href="./static/css/outliers.css" rel="stylesheet">
    <meta charset="UTF-8">
</head>

<body>
    <div class="container">
        <h1>Static outliers for Epsom PCN</h1>
        <p>There is substantial variation in prescribing behaviours, across various different areas of medicine. Some variation can be explained by demographic changes, or local policies or guidelines, but much of the remaining variation is less easy to
            explain. At <a href="https://openprescribing.net/">OpenPrescribing</a> we are piloting a number of data-driven approaches to: identify unusual prescribing, collect feedback on this prescribing to inform development of new tools to support
            prescribers and organisations to audit and review prescribing.</p>
        <p>The below reports have been developed to use “z-scores” to automatically identify prescribing patterns at a chemical level which are furthest away from “typical prescribing” and can be classified as an “outlier”. It is important to remember that
            this information was generated automatically and it is therefore likely that some of the behaviour is warranted. This report seeks only to collect information about where this variation may be warranted and where it might not. Our full analytical
            method code is openly available on GitHub <a href="https://github.com/ebmdatalab/outliers/">here</a> but briefly we calculate the number of prescriptions for each chemical in the BNF coding system using the BNF subparagraph as a denominator.
            We used the time period from 1 April 2021 to 1 August 2021. We then calculate the mean and standard deviation for each numerator and denominator pair across all practices/CCGs/PCNs. From this we can calculate the “z-score”, which is a measure
            of how many standard deviations a given practice/CCG/PCN is from the population mean. We then rank your “z-scores” to find the top 5 results where prescribing is an outlier for prescribing higher than its peers and those where it is an outlier
            for prescribing lower than its peers.</p>
        <p>The DataLab is keen to hear your feedback on the results. You can do this by completing the following <a href="https://docs.google.com/forms/d/e/1FAIpQLSeH4ai_qyetAY4UAgZSWGnYQHkXNr9efFBmQvdrBi5uuXvgnQ/viewform?usp=pp_url&entry.2016356131=+">survey</a>            or emailing us at
            <a href="mailto:ebmdatalab@phc.ox.ac.uk?subject=OpenPrescribing%20outliers%20feedback">ebmdatalab@phc.ox.ac.uk</a>. Please DO NOT INCLUDE IDENTIFIABLE PATIENT information in your feedback. All feedback is helpful, you can send short or detailed
            feedback.
        </p>
        <h2>Prescribing where Epsom PCN is higher than most</h2>
        <table border="1" class="dataframe table thead-light table-bordered table-sm" id="table_high">
  <thead>
    
    
  <tr><th>BNF Chemical</th>
      <th><abbr title="number of prescribed items containing this chemical">Chemical Items</abbr></th>
      <th>BNF Subparagraph</th>
      <th><abbr title="count of all prescribed items from this subparagraph">Subparagraph Items</abbr></th>
      <th><abbr title="Ratio of chemical items to subparagraph items">Ratio</abbr></th>
      <th><abbr title="Population mean number of chemical items prescribed">Mean</abbr></th>
      <th><abbr title="Standard Deviation">std</abbr></th>
      <th><abbr title="Number of standard deviations prescribed item count is away from the mean">Z_Score</abbr></th>
      <th>Plots</th>
    </tr></thead>
  
<tbody><tr>
      <th><a href="https://openprescribing.net/analyse/#org=pcn&amp;orgIds=U88407&amp;numIds=0205040S0&amp;denomIds=2.5.4&amp;selectedTab=summary">Prazosin hydrochloride</a><button type="button" data-toggle="collapse" data-target="#table_high_0_items" class="btn btn-default btn-xs">&#9776;</button></th>
      <td>105</td>
      <td>Alpha-adrenoceptor blocking drugs</td>
      <td>1899</td>
      <td>0.06</td>
      <td>0.00</td>
      <td>0.01</td>
      <td>7.75</td>
      <td><img class="zoom" src="data:image/png;base64,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"></td>
    </tr>
    <tr id="table_high_0_items" class="collapse"><td colspan="9" class="hiddenRow"><div><a href="https://openprescribing.net/analyse/#org=pcn&amp;orgIds=U88407&amp;numIds=0205040S0AAABAB&amp;denomIds=2.5.4&amp;selectedTab=summary" target="_blank">Prazosin 500microgram tablets : 76</a><br><a href="https://openprescribing.net/analyse/#org=pcn&amp;orgIds=U88407&amp;numIds=0205040S0AAACAC&amp;denomIds=2.5.4&amp;selectedTab=summary" target="_blank">Prazosin 1mg tablets : 29</a></div></td></tr><tr>
      <th><a href="https://openprescribing.net/analyse/#org=pcn&amp;orgIds=U88407&amp;numIds=0106060C0&amp;denomIds=1.6.6&amp;selectedTab=summary">Naldemedine</a><button type="button" data-toggle="collapse" data-target="#table_high_1_items" class="btn btn-default btn-xs">&#9776;</button></th>
      <td>1</td>
      <td>Peripheral opioid-receptor antagonists</td>
      <td>2</td>
      <td>0.50</td>
      <td>0.02</td>
      <td>0.10</td>
      <td>4.80</td>
      <td><img class="zoom" src="data:image/png;base64,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"></td>
    </tr>
    <tr id="table_high_1_items" class="collapse"><td colspan="9" class="hiddenRow"><div><a href="https://openprescribing.net/analyse/#org=pcn&amp;orgIds=U88407&amp;numIds=0106060C0AAAAAA&amp;denomIds=1.6.6&amp;selectedTab=summary" target="_blank">Naldemedine 200microgram tablets : 1</a></div></td></tr><tr>
      <th><a href="https://openprescribing.net/analyse/#org=pcn&amp;orgIds=U88407&amp;numIds=0202020U0&amp;denomIds=2.2.2&amp;selectedTab=summary">Torasemide</a><button type="button" data-toggle="collapse" data-target="#table_high_2_items" class="btn btn-default btn-xs">&#9776;</button></th>
      <td>35</td>
      <td>Loop diuretics</td>
      <td>2910</td>
      <td>0.01</td>
      <td>0.00</td>
      <td>0.00</td>
      <td>4.56</td>
      <td><img class="zoom" src="data:image/png;base64,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"></td>
    </tr>
    <tr id="table_high_2_items" class="collapse"><td colspan="9" class="hiddenRow"><div><a href="https://openprescribing.net/analyse/#org=pcn&amp;orgIds=U88407&amp;numIds=0202020U0AAAAAA&amp;denomIds=2.2.2&amp;selectedTab=summary" target="_blank">Torasemide 2.5mg tablets : 4</a><br><a href="https://openprescribing.net/analyse/#org=pcn&amp;orgIds=U88407&amp;numIds=0202020U0AAABAB&amp;denomIds=2.2.2&amp;selectedTab=summary" target="_blank">Torasemide 5mg tablets : 10</a><br><a href="https://openprescribing.net/analyse/#org=pcn&amp;orgIds=U88407&amp;numIds=0202020U0AAACAC&amp;denomIds=2.2.2&amp;selectedTab=summary" target="_blank">Torasemide 10mg tablets : 21</a></div></td></tr><tr>
      <th><a href="https://openprescribing.net/analyse/#org=pcn&amp;orgIds=U88407&amp;numIds=0408010I0&amp;denomIds=4.8.1&amp;selectedTab=summary">Ethosuximide</a><button type="button" data-toggle="collapse" data-target="#table_high_3_items" class="btn btn-default btn-xs">&#9776;</button></th>
      <td>40</td>
      <td>Control of epilepsy</td>
      <td>6135</td>
      <td>0.01</td>
      <td>0.00</td>
      <td>0.00</td>
      <td>4.30</td>
      <td><img class="zoom" src="data:image/png;base64,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"></td>
    </tr>
    <tr id="table_high_3_items" class="collapse"><td colspan="9" class="hiddenRow"><div><a href="https://openprescribing.net/analyse/#org=pcn&amp;orgIds=U88407&amp;numIds=0408010I0AAAAAA&amp;denomIds=4.8.1&amp;selectedTab=summary" target="_blank">Ethosuximide 250mg capsules : 24</a><br><a href="https://openprescribing.net/analyse/#org=pcn&amp;orgIds=U88407&amp;numIds=0408010I0AAABAB&amp;denomIds=4.8.1&amp;selectedTab=summary" target="_blank">Ethosuximide 250mg/5ml oral solution : 12</a><br><a href="https://openprescribing.net/analyse/#org=pcn&amp;orgIds=U88407&amp;numIds=0408010I0AAAKAK&amp;denomIds=4.8.1&amp;selectedTab=summary" target="_blank">Ethosuximide 250mg/5ml oral solution sugar free : 4</a></div></td></tr><tr>
      <th><a href="https://openprescribing.net/analyse/#org=pcn&amp;orgIds=U88407&amp;numIds=0101010L0&amp;denomIds=1.1.1&amp;selectedTab=summary">Aluminium and magnesium and activated simeticone</a><button type="button" data-toggle="collapse" data-target="#table_high_4_items" class="btn btn-default btn-xs">&#9776;</button></th>
      <td>1</td>
      <td>Antacids and simeticone</td>
      <td>1</td>
      <td>1.00</td>
      <td>0.16</td>
      <td>0.20</td>
      <td>4.18</td>
      <td><img class="zoom" src="data:image/png;base64,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"></td>
    </tr>
  <tr id="table_high_4_items" class="collapse"><td colspan="9" class="hiddenRow"><div><a href="https://openprescribing.net/analyse/#org=pcn&amp;orgIds=U88407&amp;numIds=0101010L0BEAAAI&amp;denomIds=1.1.1&amp;selectedTab=summary" target="_blank">Maalox Plus oral suspension : 1</a></div></td></tr></tbody></table>

        <h2>Prescribing where Epsom PCN is lower than most</h2>
        <table border="1" class="dataframe table thead-light table-bordered table-sm" id="table_low">
  <thead>
    
    
  <tr><th>BNF Chemical</th>
      <th><abbr title="number of prescribed items containing this chemical">Chemical Items</abbr></th>
      <th>BNF Subparagraph</th>
      <th><abbr title="count of all prescribed items from this subparagraph">Subparagraph Items</abbr></th>
      <th><abbr title="Ratio of chemical items to subparagraph items">Ratio</abbr></th>
      <th><abbr title="Population mean number of chemical items prescribed">Mean</abbr></th>
      <th><abbr title="Standard Deviation">std</abbr></th>
      <th><abbr title="Number of standard deviations prescribed item count is away from the mean">Z_Score</abbr></th>
      <th>Plots</th>
    </tr></thead>
  
<tbody><tr>
      <th><a href="https://openprescribing.net/analyse/#org=pcn&amp;orgIds=U88407&amp;numIds=0205040D0&amp;denomIds=2.5.4&amp;selectedTab=summary">Doxazosin mesilate</a><button type="button" data-toggle="collapse" data-target="#table_low_0_items" class="btn btn-default btn-xs">&#9776;</button></th>
      <td>1788</td>
      <td>Alpha-adrenoceptor blocking drugs</td>
      <td>1899</td>
      <td>0.94</td>
      <td>0.99</td>
      <td>0.01</td>
      <td>-4.53</td>
      <td><img class="zoom" src="data:image/png;base64,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"></td>
    </tr>
    <tr id="table_low_0_items" class="collapse"><td colspan="9" class="hiddenRow"><div><a href="https://openprescribing.net/analyse/#org=pcn&amp;orgIds=U88407&amp;numIds=0205040D0AAAAAA&amp;denomIds=2.5.4&amp;selectedTab=summary" target="_blank">Doxazosin 1mg tablets : 279</a><br><a href="https://openprescribing.net/analyse/#org=pcn&amp;orgIds=U88407&amp;numIds=0205040D0AAABAB&amp;denomIds=2.5.4&amp;selectedTab=summary" target="_blank">Doxazosin 2mg tablets : 613</a><br><a href="https://openprescribing.net/analyse/#org=pcn&amp;orgIds=U88407&amp;numIds=0205040D0AAACAC&amp;denomIds=2.5.4&amp;selectedTab=summary" target="_blank">Doxazosin 4mg tablets : 784</a><br><a href="https://openprescribing.net/analyse/#org=pcn&amp;orgIds=U88407&amp;numIds=0205040D0AAAQAQ&amp;denomIds=2.5.4&amp;selectedTab=summary" target="_blank">Doxazosin 4mg modified-release tablets : 40</a><br><a href="https://openprescribing.net/analyse/#org=pcn&amp;orgIds=U88407&amp;numIds=0205040D0AAARAR&amp;denomIds=2.5.4&amp;selectedTab=summary" target="_blank">Doxazosin 8mg modified-release tablets : 65</a><br><a href="https://openprescribing.net/analyse/#org=pcn&amp;orgIds=U88407&amp;numIds=0205040D0AABBBB&amp;denomIds=2.5.4&amp;selectedTab=summary" target="_blank">Doxazosin 8mg tablets : 1</a><br><a href="https://openprescribing.net/analyse/#org=pcn&amp;orgIds=U88407&amp;numIds=0205040D0BBADAQ&amp;denomIds=2.5.4&amp;selectedTab=summary" target="_blank">Cardura XL 4mg tablets : 3</a><br><a href="https://openprescribing.net/analyse/#org=pcn&amp;orgIds=U88407&amp;numIds=0205040D0BBAEAR&amp;denomIds=2.5.4&amp;selectedTab=summary" target="_blank">Cardura XL 8mg tablets : 3</a></div></td></tr><tr>
      <th><a href="https://openprescribing.net/analyse/#org=pcn&amp;orgIds=U88407&amp;numIds=0106060B0&amp;denomIds=1.6.6&amp;selectedTab=summary">Naloxegol</a><button type="button" data-toggle="collapse" data-target="#table_low_1_items" class="btn btn-default btn-xs">&#9776;</button></th>
      <td>1</td>
      <td>Peripheral opioid-receptor antagonists</td>
      <td>2</td>
      <td>0.50</td>
      <td>0.98</td>
      <td>0.12</td>
      <td>-3.98</td>
      <td><img class="zoom" src="data:image/png;base64,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"></td>
    </tr>
    <tr id="table_low_1_items" class="collapse"><td colspan="9" class="hiddenRow"><div><a href="https://openprescribing.net/analyse/#org=pcn&amp;orgIds=U88407&amp;numIds=0106060B0AAABAB&amp;denomIds=1.6.6&amp;selectedTab=summary" target="_blank">Naloxegol 25mg tablets : 1</a></div></td></tr><tr>
      <th><a href="https://openprescribing.net/analyse/#org=pcn&amp;orgIds=U88407&amp;numIds=0408010G0&amp;denomIds=4.8.1&amp;selectedTab=summary">Gabapentin</a><button type="button" data-toggle="collapse" data-target="#table_low_2_items" class="btn btn-default btn-xs">&#9776;</button></th>
      <td>721</td>
      <td>Control of epilepsy</td>
      <td>6135</td>
      <td>0.12</td>
      <td>0.23</td>
      <td>0.06</td>
      <td>-1.92</td>
      <td><img class="zoom" src="data:image/png;base64,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"></td>
    </tr>
    <tr id="table_low_2_items" class="collapse"><td colspan="9" class="hiddenRow"><div><a href="https://openprescribing.net/analyse/#org=pcn&amp;orgIds=U88407&amp;numIds=0408010G0AAAAAA&amp;denomIds=4.8.1&amp;selectedTab=summary" target="_blank">Gabapentin 100mg capsules : 156</a><br><a href="https://openprescribing.net/analyse/#org=pcn&amp;orgIds=U88407&amp;numIds=0408010G0AAABAB&amp;denomIds=4.8.1&amp;selectedTab=summary" target="_blank">Gabapentin 300mg capsules : 468</a><br><a href="https://openprescribing.net/analyse/#org=pcn&amp;orgIds=U88407&amp;numIds=0408010G0AAACAC&amp;denomIds=4.8.1&amp;selectedTab=summary" target="_blank">Gabapentin 400mg capsules : 28</a><br><a href="https://openprescribing.net/analyse/#org=pcn&amp;orgIds=U88407&amp;numIds=0408010G0AAAJAJ&amp;denomIds=4.8.1&amp;selectedTab=summary" target="_blank">Gabapentin 600mg tablets : 61</a><br><a href="https://openprescribing.net/analyse/#org=pcn&amp;orgIds=U88407&amp;numIds=0408010G0AAAKAK&amp;denomIds=4.8.1&amp;selectedTab=summary" target="_blank">Gabapentin 800mg tablets : 1</a><br><a href="https://openprescribing.net/analyse/#org=pcn&amp;orgIds=U88407&amp;numIds=0408010G0AABGBG&amp;denomIds=4.8.1&amp;selectedTab=summary" target="_blank">Gabapentin 50mg/ml oral solution sugar free : 7</a></div></td></tr><tr>
      <th><a href="https://openprescribing.net/analyse/#org=pcn&amp;orgIds=U88407&amp;numIds=0106050S0&amp;denomIds=1.6.5&amp;selectedTab=summary">Sodium picosulfate</a><button type="button" data-toggle="collapse" data-target="#table_low_3_items" class="btn btn-default btn-xs">&#9776;</button></th>
      <td>0</td>
      <td>Bowel cleansing preparations</td>
      <td>1</td>
      <td>0.00</td>
      <td>0.69</td>
      <td>0.37</td>
      <td>-1.87</td>
      <td><img class="zoom" src="data:image/png;base64,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"></td>
    </tr>
    <tr id="table_low_3_items" class="collapse"><td colspan="9" class="hiddenRow"><div></div></td></tr><tr>
      <th><a href="https://openprescribing.net/analyse/#org=pcn&amp;orgIds=U88407&amp;numIds=0704020AB&amp;denomIds=7.4.2&amp;selectedTab=summary">Solifenacin</a><button type="button" data-toggle="collapse" data-target="#table_low_4_items" class="btn btn-default btn-xs">&#9776;</button></th>
      <td>307</td>
      <td>Drugs for urinary frequency enuresis and incontinence</td>
      <td>1720</td>
      <td>0.18</td>
      <td>0.33</td>
      <td>0.08</td>
      <td>-1.82</td>
      <td><img class="zoom" src="data:image/png;base64,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"></td>
    </tr>
  <tr id="table_low_4_items" class="collapse"><td colspan="9" class="hiddenRow"><div><a href="https://openprescribing.net/analyse/#org=pcn&amp;orgIds=U88407&amp;numIds=0704020ABAAAAAA&amp;denomIds=7.4.2&amp;selectedTab=summary" target="_blank">Solifenacin 5mg tablets : 209</a><br><a href="https://openprescribing.net/analyse/#org=pcn&amp;orgIds=U88407&amp;numIds=0704020ABAAABAB&amp;denomIds=7.4.2&amp;selectedTab=summary" target="_blank">Solifenacin 10mg tablets : 87</a><br><a href="https://openprescribing.net/analyse/#org=pcn&amp;orgIds=U88407&amp;numIds=0704020ABAAAFAF&amp;denomIds=7.4.2&amp;selectedTab=summary" target="_blank">Solifenacin 1mg/ml oral suspension sugar free : 5</a><br><a href="https://openprescribing.net/analyse/#org=pcn&amp;orgIds=U88407&amp;numIds=0704020ABBBAAAA&amp;denomIds=7.4.2&amp;selectedTab=summary" target="_blank">Vesicare 5mg tablets : 6</a></div></td></tr></tbody></table>

    </div>
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.11.3/jquery.min.js"></script>
    <script src="https://maxcdn.bootstrapcdn.com/bootstrap/3.3.5/js/bootstrap.min.js"></script>
</body>

</html>